Zevalin works as initial therapy for follicular non-Hodgkin lymphoma

01/24/2013 | Medscape (free registration)

Initial treatment with the radioimmunotherapy Zevalin, also called 90-yttrium ibritumomab tiuxetan, allowed 35% of 59 patients with follicular non-Hodgkin lymphoma to have long-lasting responses, according to a study published in the Journal of Clinical Oncology. Patients' overall response rate at six months was 86%, and 41% of patients showed complete response. "In our opinion, radioimmunotherapy is a particularly attractive therapy for older patients, patients with significant comorbidity, or patients who refuse chemotherapy," researchers said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA